{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:26:34Z","timestamp":1790612794518,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Barenholz fund"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.nano.2018.11.012","type":"journal-article","created":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T04:06:30Z","timestamp":1544155590000},"page":"34-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Liposomal steroid nano-drug is superior to steroids as-is in mdx mouse model of Duchenne muscular dystrophy"],"prefix":"10.1016","volume":"16","author":[{"given":"Keren","family":"Turjeman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurit","family":"Yanay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moran","family":"Elbaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaelle","family":"Bavli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moria","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Rabie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yechezkel","family":"Barenholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoram","family":"Nevo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.nano.2018.11.012_bb0005","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1096\/fj.04-1956rev","article-title":"Molecular, cellular, and pharmacological therapies for Duchenne\/Becker muscular dystrophies","volume":"19","author":"Chakkalakal","year":"2005","journal-title":"FASEB J"},{"issue":"2","key":"10.1016\/j.nano.2018.11.012_bb0010","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.bbadis.2006.06.009","article-title":"Current treatment of adult Duchenne muscular dystrophy","volume":"1772","author":"Wagner","year":"2007","journal-title":"Biochim Biophys Acta (BBA) Mol Basis Dis"},{"issue":"1","key":"10.1016\/j.nano.2018.11.012_bb0015","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/01241398-200001000-00016","article-title":"Bone mineral density and fractures in boys with Duchenne muscular dystrophy","volume":"20","author":"Larson","year":"2000","journal-title":"J Pediatr Orthop"},{"issue":"8","key":"10.1016\/j.nano.2018.11.012_bb0020","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0960-8966(01)00232-2","article-title":"Three mouse models of muscular dystrophy: the natural history of strength and fatigue in dystrophin-, dystrophin\/utrophin-, and laminin \u03b12-deficient mice","volume":"11","author":"Connolly","year":"2001","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1016\/j.nano.2018.11.012_bb0025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/00003088-200544010-00003","article-title":"Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids","volume":"44","author":"Czock","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.nano.2018.11.012_bb0030","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1016\/S0960-8966(02)00101-3","article-title":"Steroids in Duchenne muscular dystrophy: from clinical trials to genomic research","volume":"12","author":"Muntoni","year":"2002","journal-title":"Neuromuscul Disord"},{"issue":"24","key":"10.1016\/j.nano.2018.11.012_bb0035","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1056\/NEJM198906153202405","article-title":"Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy","volume":"320","author":"Mendell","year":"1989","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.nano.2018.11.012_bb0040","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00198-003-1443-y","article-title":"Bone mineral density and bone metabolism in Duchenne muscular dystrophy","volume":"14","author":"Bianchi","year":"2003","journal-title":"Osteoporos Int"},{"issue":"19","key":"10.1016\/j.nano.2018.11.012_bb0045","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1212\/01.wnl.0000260974.41514.83","article-title":"Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy","volume":"68","author":"King","year":"2007","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.nano.2018.11.012_bb0050","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.nmd.2007.05.008","article-title":"Low bone mineral density and decreased bone turnover in Duchenne muscular dystrophy","volume":"17","author":"S\u00f6derpalm","year":"2007","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1016\/j.nano.2018.11.012_bb0055","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1080\/10717544.2018.1447050","article-title":"Targeted delivery of hyaluronic acid-coated solid lipid nanoparticles for rheumatoid arthritis therapy","volume":"25","author":"Zhou","year":"2018","journal-title":"Drug Deliv"},{"issue":"Supplementum 2","key":"10.1016\/j.nano.2018.11.012_bb0060","doi-asserted-by":"crossref","first-page":"S281","DOI":"10.33549\/physiolres.933977","article-title":"Polymer-drug conjugates in inflammation treatment","volume":"67","author":"Koziolov\u00e1","year":"2018","journal-title":"Physiol Res"},{"issue":"9","key":"10.1016\/j.nano.2018.11.012_bb0065","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/1061186X.2016.1236262","article-title":"Liposomal nano-drugs based on amphipathic weak acid steroid prodrugs for treatment of inflammatory diseases","volume":"24","author":"Turjeman","year":"2016","journal-title":"J Drug Target"},{"issue":"11","key":"10.1016\/j.nano.2018.11.012_bb0070","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1177\/0961203316636468","article-title":"A liposomal steroid nano-drug for treating systemic lupus erythematosus","volume":"25","author":"Moallem","year":"2016","journal-title":"Lupus"},{"issue":"10","key":"10.1016\/j.nano.2018.11.012_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025721","article-title":"Fabrication principles and their contribution to the superior in vivo therapeutic efficacy of nano-liposomes remote loaded with glucocorticoids","volume":"6","author":"Avnir","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.nano.2018.11.012_bb0080","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jconrel.2011.12.024","article-title":"Glucocorticoids in nano-liposomes administered intravenously and subcutaneously to adjuvant arthritis rats are superior to the free drugs in suppressing arthritis and inflammatory cytokines","volume":"160","author":"Ulmansky","year":"2012","journal-title":"J Control Release"},{"issue":"7","key":"10.1016\/j.nano.2018.11.012_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130442","article-title":"Nano-drugs based on nano sterically stabilized liposomes for the treatment of inflammatory neurodegenerative diseases","volume":"10","author":"Turjeman","year":"2015","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.nano.2018.11.012_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072722","article-title":"Glucocorticosteroids in nano-sterically stabilized liposomes are efficacious for elimination of the acute symptoms of experimental cerebral malaria","volume":"8","author":"Waknine-Grinberg","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.nano.2018.11.012_bb0095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/jps.2600700217","article-title":"Initial rate studies of hydrolysis and acyl migration in methylprednisolone 21-hemisuccinate and 17-hemisuccinate","volume":"70","author":"Anderson","year":"1981","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.nano.2018.11.012_bb0100","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0076-6879(03)67017-5","article-title":"Enzymatic assays for quality control and pharmacokinetics of liposome formulations: comparison with nonenzymatic conventional methodologies","volume":"367","author":"Shmeeda","year":"2003","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.nano.2018.11.012_bb0105","series-title":"The mdx-amplification-resistant mutation system assay, a simple and rapid polymerase chain reaction-based detection of the mdx allele","author":"Amalfitano","year":"1996"},{"issue":"4","key":"10.1016\/j.nano.2018.11.012_bb0110","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.nmd.2010.02.002","article-title":"Improved muscle strength and mobility in the dy2J\/dy2J mouse with merosin deficient congenital muscular dystrophy treated with glatiramer acetate","volume":"20","author":"Dadush","year":"2010","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"10.1016\/j.nano.2018.11.012_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018049","article-title":"The Ras antagonist, farnesylthiosalicylic acid (FTS), decreases fibrosis and improves muscle strength in dy2J\/dy2J mouse model of muscular dystrophy","volume":"6","author":"Nevo","year":"2011","journal-title":"PLoS One"},{"issue":"45","key":"10.1016\/j.nano.2018.11.012_bb0120","doi-asserted-by":"crossref","first-page":"16876","DOI":"10.1073\/pnas.0604234103","article-title":"Depression induces bone loss through stimulation of the sympathetic nervous system","volume":"103","author":"Yirmiya","year":"2006","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.nano.2018.11.012_bb0125","first-page":"61","article-title":"Micro-tomographic imaging for the nondestructive evaluation of trabecular bone architecture","volume":"40","author":"M\u00fcller","year":"1997","journal-title":"Stud Health Technol Inform"},{"issue":"7","key":"10.1016\/j.nano.2018.11.012_bb0130","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1359\/jbmr.1999.14.7.1167","article-title":"Direct three-dimensional morphometric analysis of human cancellous bone: microstructural data from spine, femur, iliac crest, and calcaneus","volume":"14","author":"Hildebrand","year":"1999","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.nano.2018.11.012_bb0135","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/art.23230","article-title":"Amphipathic weak acid glucocorticoid prodrugs remote-loaded into sterically stabilized nanoliposomes evaluated in arthritic rats and in a beagle dog: a novel approach to treating autoimmune arthritis","volume":"58","author":"Avnir","year":"2008","journal-title":"Arthritis Rheumatol"},{"issue":"7140","key":"10.1016\/j.nano.2018.11.012_bb0140","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations","volume":"447","author":"Welch","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.nano.2018.11.012_bb0145","series-title":"FDA grants accelerated approval to first drug for Duchenne muscular dystrophy","author":"Food","year":"2016"},{"issue":"10119","key":"10.1016\/j.nano.2018.11.012_bb0150","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","article-title":"Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study","volume":"391","author":"McDonald","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.nano.2018.11.012_bb0155","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1001\/archneur.1991.00530160047012","article-title":"Prednisone in Duchenne dystrophy: a randomized, controlled trial defining the time course and dose response","volume":"48","author":"Griggs","year":"1991","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.nano.2018.11.012_bb0160","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1474-4422(09)70272-8","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.nano.2018.11.012_bb0165","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.nano.2018.11.012_bb0170","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/ana.24370","article-title":"Genetic modifiers of ambulation in the cooperative international neuromuscular research group Duchenne natural history study","volume":"77","author":"Bello","year":"2015","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.nano.2018.11.012_bb0175","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","article-title":"Long-term side effects of glucocorticoids","volume":"15","author":"Oray","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"10.1016\/j.nano.2018.11.012_bb0180","first-page":"16","article-title":"Prednisolone treatment and restricted physical activity further compromise bone of mdx mice","volume":"12","author":"Novotny","year":"2012","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"1","key":"10.1016\/j.nano.2018.11.012_bb0185","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7570\/kjo.2015.24.1.9","article-title":"Diverse abnormal body composition phenotypes: interaction between muscle, fat, and bone","volume":"24","author":"Kim","year":"2015","journal-title":"Korean J Obes"},{"issue":"4","key":"10.1016\/j.nano.2018.11.012_bb0190","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1682\/JRRD.2008.09.0136","article-title":"Whole-body vibration as potential intervention for people with low bone mineral density and osteoporosis: a review","volume":"46","author":"de Zepetnek","year":"2009","journal-title":"J Rehabil Res Dev"},{"issue":"2","key":"10.1016\/j.nano.2018.11.012_bb0195","doi-asserted-by":"crossref","first-page":"E128","DOI":"10.1208\/aapsj0902015","article-title":"Targeted pharmaceutical nanocarriers for cancer therapy and imaging","volume":"9","author":"Torchilin","year":"2007","journal-title":"AAPS J"},{"issue":"7","key":"10.1016\/j.nano.2018.11.012_bb0200","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/(SICI)1097-4598(199907)22:7<889::AID-MUS12>3.0.CO;2-B","article-title":"Transforming growth factor-\u03b22 is elevated in skeletal muscle disorders","volume":"22","author":"Murakami","year":"1999","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.nano.2018.11.012_bb0205","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/1097-4598(200103)24:3<428::AID-MUS1018>3.0.CO;2-E","article-title":"Impact of prednisone on TGF-\u03b21 and collagen in diaphragm muscle from mdx mice","volume":"24","author":"Hartel","year":"2001","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.nano.2018.11.012_bb0210","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003725.pub3","article-title":"Glucocorticoid corticosteroids for Duchenne muscular dystrophy","author":"Manzur","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.nano.2018.11.012_bb0215","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0959-437X(02)00309-X","article-title":"Muscular dystrophies involving the dystrophin\u2013glycoprotein complex: an overview of current mouse models","volume":"12","author":"Durbeej","year":"2002","journal-title":"Curr Opin Genet Dev"},{"issue":"2","key":"10.1016\/j.nano.2018.11.012_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088360","article-title":"Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy","volume":"9","author":"Janssen","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.nano.2018.11.012_bb0225","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/mus.21327","article-title":"Effects of prednisolone on skeletal muscle contractility in mdx mice","volume":"40","author":"Baltgalvis","year":"2009","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.nano.2018.11.012_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0034204","article-title":"Glucocorticoid-treated mice are an inappropriate positive control for long-term preclinical studies in the mdx mouse","volume":"7","author":"Sali","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.nano.2018.11.012_bb0235","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1124\/jpet.102.041343","article-title":"Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1","volume":"304","author":"De Luca","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.nano.2018.11.012_bb0240","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0960-8966(99)00126-1","article-title":"Pre-clinical screening of drugs using the mdx mouse","volume":"10","author":"Granchelli","year":"2000","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"10.1016\/j.nano.2018.11.012_bb0245","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.nmd.2007.02.005","article-title":"Strength and corticosteroid responsiveness of mdx mice is unchanged by RAG2 gene knockout","volume":"17","author":"Golumbek","year":"2007","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"10.1016\/j.nano.2018.11.012_bb0250","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0022-510X(94)00276-T","article-title":"Mdx mice show progressive weakness and muscle deterioration with age","volume":"129","author":"Pastoret","year":"1995","journal-title":"J Neurol Sci"},{"issue":"1","key":"10.1016\/j.nano.2018.11.012_bb0255","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/mus.20646","article-title":"Weekly oral prednisolone improves survival and strength in male mdx mice","volume":"35","author":"Keeling","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nano.2018.11.012_bb0260","first-page":"1","article-title":"Can quantitative muscle strength and functional motor ability differentiate the influence of age and corticosteroids in ambulatory boys with Duchenne muscular dystrophy?","volume":"8","author":"Buckon","year":"2016","journal-title":"PLoS Curr"},{"issue":"3","key":"10.1016\/j.nano.2018.11.012_bb0265","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154996341830563X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154996341830563X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T19:10:39Z","timestamp":1573067439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154996341830563X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":53,"alternative-id":["S154996341830563X"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2018.11.012","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liposomal steroid nano-drug is superior to steroids as-is in mdx mouse model of Duchenne muscular dystrophy","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2018.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}